{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04174898",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Protocol LMC-101"
      },
      "Organization": {
        "OrgFullName": "Landmark Medical Centre Sdn Bhd",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "MSC Infusion for Anti-aging and Regenerative Therapy",
      "OfficialTitle": "Human Mesenchymal Stem Cell (hMSC) Infusion for Anti-Aging and REGENerative Therapy",
      "Acronym": "REGEN"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2019",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 15, 2020",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 14, 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 14, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 19, 2019",
      "StudyFirstSubmitQCDate": "November 20, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 22, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 20, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 22, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Dr Lucas Luk Tien Wee",
        "ResponsiblePartyInvestigatorTitle": "Director, Consultant Obstetrician & Gynaecologist",
        "ResponsiblePartyInvestigatorAffiliation": "Landmark Medical Centre Sdn Bhd"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Landmark Medical Centre Sdn Bhd",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "CytoMed Therapeutics Pte Ltd",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population",
      "DetailedDescription": "100million human mesenchymal stem cells will be infused into study subjects. They will be followed up for both objective and subjective measures of 'anti-aging'. Biochemical markers such as male and female hormones and other parameters of well being will be measured. A questionnaire will also be filled pre and post infusion to ascertain one's well-being (Adapted from SF-36).\n\nSource of MSCs - Autologous (Adipose tissue) or Allogenic (Adipose tissue or umbilical cord)\n\nMSC production and storage will be performed in a GMP certified laboratory setting."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Aging Well",
          "Regenerative Medicine"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "human Mesenchymal Stem Cells (hMSC)",
          "Anti-Aging",
          "Regenerative Medicine",
          "Adipose Derived MSCs",
          "Umbilical Cord Derived MSCs",
          "Autologous hMSC",
          "Allogenic hMSC"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "Prospective, Unblinded, non-randomized",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "100",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Treatment Population",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human Mesenchymal Stem Cell (MSC) infusion therapy"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "human Mesenchymal Stem Cell (MSC) infusion therapy",
            "InterventionDescription": "Subjects will be infused with 100million human MSCs",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Treatment Population"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate number of Participants with Treatment-Related Adverse Events",
            "PrimaryOutcomeDescription": "The safety of both Adipose derived and Umbilical Cord derived MSCs (both of Autologous and Allogenic sources) will be studied in clinical trial subjects. Adverse events will be documented and patients will be followed up over a period of 1 year post-infusion, to assess their well being. Clinical assessments and biochemical tests will be performed over the study period.",
            "PrimaryOutcomeTimeFrame": "1 year"
          },
          {
            "PrimaryOutcomeMeasure": "Improvement in General Well-Being, as assessed by our 'Quality of Life' Questionnaire, adapted from SF36.",
            "PrimaryOutcomeDescription": "A 'Quality of Life' Questionnaire will be filled by Trial Participants pre and post-infusion therapy. This questionnaire has been adapted from SF36 and scales of 1-5 are used to grade an individual's well being - A score of 1 being worse and 5 meaning a better outcome.",
            "PrimaryOutcomeTimeFrame": "1 year"
          },
          {
            "PrimaryOutcomeMeasure": "Change in inflammatory marker levels",
            "PrimaryOutcomeDescription": "IL-6, TNF alpha and CRP have been widely studied as markers of aging. These will be assessed in our trial subjects to ascertain if hMSC infusion results in any reduction in these inflammatory markers",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in medication dosage (if any)",
            "SecondaryOutcomeDescription": "IF patients with chronic medical conditions such as hypertension are on medication, patients will be assessed if hMSC infusion results in any change in required medication dosage",
            "SecondaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Change from baseline, in plasma Glucose levels, over 52 weeks",
            "OtherOutcomeDescription": "fasting glucose levels and HbA1c Levels will be assessed pre and post-infusion",
            "OtherOutcomeTimeFrame": "1 year"
          },
          {
            "OtherOutcomeMeasure": "Fasting lipid profile",
            "OtherOutcomeDescription": "Fasting lipid profile will be assessed pre and post-infusion",
            "OtherOutcomeTimeFrame": "1 year"
          },
          {
            "OtherOutcomeMeasure": "Change in Hormonal Profile",
            "OtherOutcomeDescription": "FSH, LH, Estradiol, Progesterone, Testosterone Levels assessed pre and post-infusion",
            "OtherOutcomeTimeFrame": "1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAll patients >18yrs old, who are able to read, write and understand Informed Consent form, regarding the experimental nature of this therapy.\nAll Healthy Subjects are eligible for this study\nSubjects with stable pre-morbid medical conditions, not requiring changes to their current medical therapy for >6 months prior to enrolling in this study, are eligible.\n\nExclusion Criteria:\n\nUncontrolled blood pressure at the time of enrollment: systolic pressure >160 mmHg and/or diastolic blood pressure > 100 mmHg.\nHaving evidence related to renal dysfunction: creatinine > 1.5 mg/dl or (>133 mmol/L) for men. creatinine > 1.4 mg/dl or (>124 mmol/L) for woman. eGRF < 40 ml/ min Proteinuria > 300 mg/day\nSevere heart disease (NYHA 3/4 or congestive heart failure)\nSevere liver disease (liver enzymes >2x baseline, or evidence of coagulopathy)\nEvidence of ketoacidosis at the time of selection.\nEvidence of ongoing or frequent hypoglycemia.\nSevere infection at time of selection\nInfected with hepatitis B virus or hepatitis C or tuberculosis.\nSerious allergic constitution\nNeoplasm detected before/during screening or raised tumour markers CA125 (Females), CA15.3 (Females), CEA, CA19.9, Alpha Fetoprotein (AFP), PSA (Males)\nPatients who are currently participating in another clinical study involving experimenting drugs and/or medical equipment.\nPregnant or Breastfeeding\nPatients who are unable to perform the tests and assessments needed for the study\nPatients who do not agree to participate in the study.\nPatients with pre-morbid medical conditions, who have recently had alterations in their treatment regime (<6 months).",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Lucas TW Luk, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+6072783333",
            "CentralContactEMail": "drlucas@landmarkmedical.com.my"
          },
          {
            "CentralContactName": "WeeKiat Tan, PhD",
            "CentralContactRole": "Contact",
            "CentralContactEMail": "weekiattan@cytomed.sg"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Landmark Medical Centre Sdn Bhd",
            "LocationCity": "Johor Bahru",
            "LocationState": "Johor Darul Takzim",
            "LocationZip": "80000",
            "LocationCountry": "Malaysia",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Dr Lucas Luk, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+6072783333",
                  "LocationContactEMail": "drlucas@landmarkmedical.com.my"
                },
                {
                  "LocationContactName": "Nelling Ong",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+6072783333",
                  "LocationContactEMail": "nellieong@landmarkmedical.com.my"
                },
                {
                  "LocationContactName": "Dr Lucas Luk, MB BCh BAO (MD)",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    }
  }
}